On October 11, 2019, Edgewater Capital Partners announced they have entered into an agreement to acquire Haematologic Technologies Incorporated, a leading provider of biologic products and GMP compliant assay development and testing services to the biopharmaceutical industry.
Haematologic Technologies is a leading provider of research reagents, customized blood collection tubes and protein biochemistry services including assay development, validation, and GMP release and stability testing.
Edgewater Capital Partners is a sector focused private equity firm dedicated to investing in lower middle-market performance materials businesses, with experience and expertise in specialty chemicals, life sciences, engineered components, and advanced materials.
Through this acquisition, Haematologic Technologies gains a partner that will assist the Company in its next phase of growth as it continues to provide exceptional and innovative products and services to its clients and seeks to become the outsourced service provider of choice for the biologics industry.
Crosstree acted as the exclusive financial advisor to Haematologic Technologies.
This transaction further strengthens Crosstree’s extensive advisory experience with both research reagents and contract research laboratories.